ClinicalTrials.gg

Program

petrelintide

Also written as “Petrelintide” and “ZP8396”.

Its studies are mostly in Obesity · Overweight · Renal Insufficiency, led by 2 companies.

Furthest: phase 3, since Oct 25, 202411 company-led studies, 5 open or runningCo-development: Zealand Pharma and Roche, Mar 2025Next primary completion: Apr 12, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zealand Pharma71 open or runningphase 2since Oct 25, 2024Oct 14, 2021Apr 12, 2027phase 1 · NCT07682818
Hoffmann-La Roche44 open or runningphase 3since Sep 11, 2026May 11, 2026Nov 12, 2027phase 2 · NCT07589686
  • Named in Hoffmann-La Roche’s own pipeline as RG6849 petrelintide (Zealand), phase 3, as of Oct 22, 2026 (source).

Also a collaborator on its studies: parexel, icon-clinical-research and icon-plc.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 14, 2021First study: phase 1 study in OverweightNew to Zealand PharmaZealand Pharma · NCT05096598 · 64 enrolled · Germany
  2. Oct 28, 2022Phase 1 study in OverweightZealand Pharma · NCT05613387 · 68 enrolled · Germany
  3. Oct 25, 2024Phase 2 study in ObesityZealand Pharma · NCT06662539 · 493 enrolled · United States, Poland, Romania
  4. Apr 11, 2025Phase 2 study in OverweightZealand Pharma · NCT06926842 · 221 enrolled · United States
  5. Jul 10, 2025Phase 1 study in Renal InsufficiencyZealand Pharma · NCT07076030 · 39 enrolled · Germany
  6. Dec 11, 2025Phase 1 study in ObesityZealand Pharma · NCT07338214 · 48 enrolled · Germany
  7. May 11, 2026Hoffmann-La Roche's first study: phase 2 study in ObesityNew to Hoffmann-La RocheHoffmann-La Roche · NCT07589686 · 486 planned
  8. Jun 26, 2026Phase 1 study in Impaired Hepatic FunctionZealand Pharma · NCT07682818 · 36 planned · Poland, Slovakia
  9. Sep 11, 20263 phase 3 studies in ObesityPhase 3 reachedHoffmann-La Roche · NCT07843498, NCT07843485, NCT07843472

Ahead

  1. Apr 12, 2027Primary completion: phase 1 study in Impaired Hepatic FunctionZealand Pharma · NCT07682818
  2. Nov 12, 2027Primary completion: phase 2 study in ObesityHoffmann-La Roche · NCT07589686
  3. Oct 20, 2028Primary completion: phase 3 study in ObesityHoffmann-La Roche · NCT07843485
  4. Dec 21, 2028Primary completion: phase 3 study in ObesityHoffmann-La Roche · NCT07843498

TargetBeta

CALCR →read by rule
“Petrelintide is a long-acting amylin analog in development for weight management.”study text, by rule · the study

Other programs on CALCR

ProgramCompanyFurthest phaseStudies
cagrilintideNovo Nordiskphase 350
zenagamtideNovo Nordiskphase 335
ABBV-295AbbViephase 25
PF-08653945Pfizerphase 22
GUB014295AbbViephase 11
CagriSema ANovo Nordiskphase 11

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07843472Obesity · United States, Taiwan, United Kingdom3RecruitingHoffmann-La RocheJul 28, 20302,500
NCT07843498Obesity · United States3RecruitingHoffmann-La RocheDec 21, 20283,900
NCT07843485Obesity · United States3RecruitingHoffmann-La RocheOct 20, 2028600
NCT07682818Impaired Hepatic Function · Poland, Slovakia1RecruitingZealand PharmaApr 12, 202736
NCT07589686Obesity2Not yet recruitingHoffmann-La RocheNov 12, 2027486
NCT07338214Obesity · Germany1CompletedZealand PharmaMar 31, 202648
NCT07076030Renal Insufficiency · Germany1CompletedZealand PharmaNov 25, 202539
NCT06926842Overweight · United States2CompletedZealand PharmaAug 13, 2026221
NCT06662539Obesity · United States, Poland, Romania2CompletedZealand PharmaSep 30, 2025493
NCT05613387Overweight · Germany1CompletedZealand PharmaJun 13, 202468
NCT05096598Overweight · Germany1CompletedZealand PharmaJan 12, 202364

How it is read

Names in the registry

  • “Petrelintide”, 9 entries
  • “ZP8396”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.